Surrogating Physician-recorded SCORE2 Risk Calculator Inputs by Using Auxiliary Data (Frauenherzen)

February 12, 2025 updated by: Insel Gruppe AG, University Hospital Bern

Surrogating Physician-recorded SCORE2 Risk Calculator Inputs by Using Auxiliary Data - A Cross-sectional Study in Apparently Healthy Women Aged 40 to 69 Years (Frauenherzen)

The goal of the clinical trial is to assess whether the data collected from wearable devices can reduce the uncertainty in predicting the cardiovascular disease (CVD) risk in women aged 40-69 years in a situation where information about the blood pressure and blood lipids are unavailable.

Participants will:

  • Complete a screening and baseline assessment, including blood sample collection and vital parameter measurement.
  • Wear a wearable device for one week.
  • Fill in a work and sleep journal.
  • Complete a last visit assessment.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

250

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Bern, Switzerland, 3010
        • Recruiting
        • University Hospital of Bern, Department of Gynecological Endocrinology & Reproductive Medicine
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The study will include women aged 40 to 69 years who meet the inclusion and exclusion criteria.

Description

Inclusion Criteria:

  • Fluency in German (written and oral).
  • Ownership of a smartphone.
  • Signing the informed consent form.

Exclusion Criteria:

  • Diagnosis of cardiovascular disease.
  • Diagnosis of diabetes mellitus.
  • Diagnosis of chronic kidney disease.
  • Diagnosis of familial hypercholesterolemia.
  • Incapable of providing informed consent.
  • Current employment at the Section Gynecological Endocrinology and Reproductive Medicine of the Department for Obstetrics and Gynecology at the Inselspital Bern or any other professional relation to one of the study project leaders / investigators.
  • Concurrent participation in a clinical intervention study.
  • Inability to comply with the study procedures for any reason, including language comprehension, psychiatric illness, general inability to get to the study site.
  • Participant's smartphone not compatible with Fitrockr.
  • Technical inability of participant's smartphone to connect to the smartwatch.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Apparently healthy women aged 40 to 69 years

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reduction in CVD Risk Prediction Uncertainty Using Wearable Data
Time Frame: After 7-day wearable data collection period.
Assessment of the reduction in prediction uncertainty of cardiovascular disease (CVD) risk in women aged 40-69 years when wearable-derived data (e.g., heart rate, daily step count) is used to replace missing physician-recorded inputs (e.g., blood pressure and lipid levels). The reduction will be quantified using the Continuous Ranked Probability Score (CRPS), whereby smaller CRPS values indicate improved performance. An improvement is considered substantial if introducing wearable data reduces CRPS by at least 5%.
After 7-day wearable data collection period.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Identification of wearable data that improve cardiovascular disease risk prediction without clinical key inputs
Time Frame: After 7-day wearable data collection period.
Identifying specific data from wearable devices that most effectively reduce uncertainty in predicting CVD risk in the absence of information on blood pressure, blood lipids, and the presence or absence of metabolic syndrome. To achieve this, statistical and machine learning methods capable of handling irregularly samples time series of bio-signals recorded by the wearable devices will be applied.
After 7-day wearable data collection period.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Petra Stute, Prof., University Hospital of Bern, Department of Gynecological Endocrinology & Reproductive Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 24, 2023

Primary Completion (Estimated)

March 1, 2025

Study Completion (Estimated)

March 1, 2025

Study Registration Dates

First Submitted

January 20, 2025

First Submitted That Met QC Criteria

February 12, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 12, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2022-02080

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.